Unanimous vote lights path to FDA approval for LCA gene therapy

All 16 members of the FDA’s Cellular, Tissue and Gene Therapies Advisory Committee voted to recommend Spark Therapeutic’s Luxterna (voretigene neparvovec) for regulatory approval at a landmark hearing on October 12.
Source: Daily Dose of Eye Care

https://www.lvcenter4sight.com/unanimous-vote-lights-path-to-fda-approval-for-lca-gene-therapy/

Comments

Popular posts from this blog

AGTC Announces Topline Interim Six-Month Data of XLRS Gene Therapy from Ongoing Phase 1/2 Clinical Trial

What to Know About Resveratrol

The Hidden Perils of Eye Rubbing